Merrill puts OSI at buy

OSI Pharmaceuticals, Inc. was rated by Merrill Lynch analyst Eric Ende at a buy on possible weak Tarceva sales being reported by Genentech, Inc. on Tuesday. The analyst would use the weakness as a buying opportunity because he expects Tarceva sales to rebound in the fourth quarter. Merrill believes U.S. Tarceva sales to come in at about $105 million, below consensus of $110 million. Shares of the Melville, N.Y.-based pharmaceutical company were down 37 cents, or 0.98%, at $37.42. (Nasdaq: OSIP)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.